Cytodyn Inc Plans on Moving Forward With COVID-19 Trial Transcript
(technical difficulty) our product, leronlimab, which was referred to as PRO 140 in past publication, has done very nicely in the clinical trial for HIV combination therapy. So the mechanism of action is it binds to CCR5. Now people with COVID-19 die because of cytokine storm, which all have CCR5, same receptor that we bind to stop HIV.
We have done over 840 patients with zero serious adverse events attributed to the drug. So being a product that has hardly any toxicity or side effect, that was a very big start for us with the FDA when we say that our scientists believe we can stop cytokine storm, which that's the reason people die because of ARDS, acute respiratory distress syndrome.
So when the doctor from New York believed in this product and they gave it to some patients immediately, he wanted to give to extra patients after the first two -- the first four -- two of them extubated. One of the patients was alert immediately and extubated himself, got out of the ventilator, got out of ICU. Then he wanted to give to more patients.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
